Table 8

Groups	Parameters	Total lipids (g/L)	Triglycerides (mg/dl)	Total cholesterol (mg/dl)	LDL- cholesterol (mg/dl)	HDL- cholesterol (mg/dl)	vLDL- cholesterol (mg/dl)	LDL/ HDL	Total chol./ HDL	HMGCo-A/ mevalonate
Normal		3.16±0.19^c	42.75±1.37^a	72.76±1.24^b	29.90±0.63^b	34.44±1.04^a	8.55±0.27^a	0.87±0.02^b	2.11±0.05^b	1.31±0.01^b
Diabetic control		4.71±0.20^a	46.07±2.38^a	76.76±1.17^a	37.49±2.79^a	30.05±1.22^a	9.21±0.07^a	1.27±0.12^a	2.56±0.06^a	1.30±1.01^b
Diabetic treated with 4b		4.03±0.08^b	42.28±0.54^a	67.89±0.90^c	25.77±1.55^b	33.67±2.33^a	8.46±0.30^a	1.31±0.06^a	2.06±0.12^b	1.59±2.10^a
F-probability		P<0.001	p>0.05	P<0.001	P<0.01	p>0.05	p>0.05	P<0.01	P<0.01	P<0.001
LSD at 5% level		0.49	-	3.36	5.65	-	-	0.236	0.25	0.042
LSD at 1% level		0.68	-	4.65	7.82	-	-	0.326	0.35	0.058

Table 8: Effect of pyrimido[1,6-a]quinazoline derivative 4b on serum lipid profile in n5-STZ induced type 2 diabetic male rats.